Your browser doesn't support javascript.
Tofacitinib in the treatment of ulcerative colitis : A position paper issued by the Inflammatory Bowel Disease Working Group of the Austrian Society of Gastroenterology and Hepatology (ÖGGH).
Kutschera, Maximilian; Novacek, Gottfried; Reinisch, Walter; Högenauer, Christoph; Petritsch, Wolfgang; Haas, Thomas; Moschen, Alexander; Dejaco, Clemens.
  • Kutschera M; Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
  • Novacek G; Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
  • Reinisch W; Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
  • Högenauer C; Division of Gastroenterology and Hepatology, Medical Department, Medical University of Graz, Graz, Austria.
  • Petritsch W; Division of Gastroenterology and Hepatology, Medical Department, Medical University of Graz, Graz, Austria.
  • Haas T; Gastroenterology Office (Darmpraxis), Salzburg, Austria.
  • Moschen A; Second Medical Department, Kepler University Hospital, Linz, Austria.
  • Dejaco C; Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria. clemens.dejaco@meduniwien.ac.at.
Wien Klin Wochenschr ; 2022 Dec 01.
Article in English | MEDLINE | ID: covidwho-2242416
ABSTRACT
Ulcerative colitis (UC) is one of the main forms of inflammatory bowel disease (IBD). Despite the widening range of drug treatment options, primary nonresponse, secondary loss of response as well as adverse events call for additional treatment alternatives.Tofacitinib is an oral small-molecule drug of the class of Janus kinase inhibitors which, in the European Union, was approved for the treatment of moderate to severe active UC in August 2018. This position paper, drawn up by the IBD Working Group of the Austrian Society of Gastroenterology and Hepatology, summarizes the mechanism of action, clinical development, marketing authorization status, efficacy and safety of tofacitinib. Also, by providing a synopsis of available data from both pivotal and post-marketing studies, clinical aspects of specific interest are highlighted and discussed.The available body of evidence indicates that tofacitinib is an additional effective medication for the treatment of UC that exhibits a good safety profile. This position paper aims at optimizing the safe and effective use of tofacitinib in daily clinical practice.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Year: 2022 Document Type: Article Affiliation country: S00508-022-02110-2

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Year: 2022 Document Type: Article Affiliation country: S00508-022-02110-2